Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 19 September 2017 | By Michael Mezher
In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for biomarker developers to engage with FDA.
"A qualified biomarker can be used in multiple drug development programs without the need for [the Center for Drug Evaluation and Research] CDER to reconfirm the suitability of the biomarker's qualified context of use," said Marianne Noone, a regulatory project manager at CDER's Office of Translational Sciences.
To date, FDA says it has qualified six biomarkers and received 20 submissions to the program.
FDA's biomarker qualification program was recently updated to meet requirements set by the 21st Century Cures Act, which calls on FDA to issue guidance detailing a formal multi-stage process for biomarker qualification with set time frames for the review of letters, qualification plans and full qualification packages.
Under the process, biomarker qualification begins when a developer submits a letter of intent to FDA detailing information about the biomarker, its context of use, how it will be measured and the need it is meant to address. Then, Noone said, FDA will accept or deny the submission based on whether the biomarker "has the potential to address an unmet medical need in drug development."
After the letter of intent is accepted, the developer must then submit a qualification plan to FDA that details the proposed plan to generate evidence in support of the biomarker for the proposed context of use.
"The [qualification plan] should include detailed information on the suitability of the biomarker measurement method, as well as summary data on completed studies and study designs for planned future studies to confirm the usefulness of the biomarker in drug development," Noone said.
Once approved, the developer will then be instructed to complete and submit their full qualification package, which Noone said should include "all accumulated data to support the biomarker." FDA will then issue a determination of whether the biomarker is suitable in the same context of use in any drug development program.
Noone also notes that biomarker developers may enter the process at any of the three stages based on the level of evidence they have to support their biomarker.
In a separate presentation, Kylie Haskins, a scientific lead at the Office of Translational Sciences, said there are two main opportunities for biomarker developers to interact with FDA before moving to the formal biomarker qualification program.
The first is by requesting a Critical Path Innovation Meeting (CIPM), which offers an early opportunity for developers to meet with the agency to discuss the potential of the proposed biomarker before it's ready for submission to the biomarker qualification program and may cover scientific, medical and regulatory issues.
Beyond that, the next way developers can interact with FDA is by requesting a letter of support for their biomarker. So far, FDA has issued letters of support for 14 biomarkers, the most recent of which is for a biomarker aimed at identifying patients in clinical trials for mild traumatic brain injury who are more likely to develop a long-term disability.
To obtain a letter of support, developers should provide FDA with a description of the biomarker and how it will be used, measured and assessed, as well as a rationale for how the biomarker is useful.
According to Haskins, letters of support do not connote qualification or offer an endorsement of specific biomarker tests, but can be useful in demonstrating FDA's support for further development of the biomarker.
Opportunities to Engage With the FDA About Qualification During Biomarker Development
The Biomarker Qualification Process: A Roadmap for Requestors
Slides 1, 2
Tags: Biomarkers, Biomarker Qualification Program, Critical Path Innovation Meeting, 21st Century Cures
Regulatory Focus newsletters
All the biggest regulatory news and happenings.